50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today

Group 1 - Xenon Pharmaceuticals (XENE) shares increased by 49.6% to $62.76 following the announcement that its epilepsy drug azetukalner achieved a 53.2% reduction in seizure frequency in a Phase 3 study [1] - Relmada Therapeutics (RLMD) saw a 61.1% rise to $7.17 based on a 92% response rate from its bladder cancer treatment NDV-01, with projected peak sales of $2.3 billion [1] - Both companies are positioned for commercialization after clearing significant regulatory hurdles and demonstrating strong clinical efficacy data [1] Group 2 - Xenon is targeting an NDA submission to the FDA in the second half of 2026, with a consensus of 21 analysts giving it Buy or Strong Buy ratings and an average price target of $56.50 [1] - The company has $716 million in cash, providing a financial runway into the second half of 2027, mitigating near-term financing risks [1] - Relmada's NDV-01 is designed for community urology settings, addressing a significant market as 70-80% of non-muscle-invasive bladder cancer patients are treated outside academic centers [1] Group 3 - The next milestone for XENE is the formal NDA submission later this year, while RLMD is expected to release full 12-month data and provide updates on Phase 3 trial initiation timelines [1]